title: Response.
authors.affiliation: Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Electronic address: anthony.durmowicz@fda.hhs.gov.
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Durmowicz
authors.affiliation: Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Witzmann
authors.affiliation: Office of New Drugs and the Office of Drug Evaluation 2, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Rosebraugh
authors.affiliation: Division of Pulmonary, Allergy and Rheumatology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
authors.forename: Badrul A
authors.initials: BA
authors.lastname: Chowdhury
mesh_terms: D000627:Aminophenols / Q000627:therapeutic use*; D002712:Chlorides / Q000032:analysis*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods*; D015363:Quinolones / Q000627:therapeutic use*; D013542:Sweat / Q000737:chemistry*
chemical_list: D000627:Aminophenols; D002712:Chlorides; D015363:Quinolones